Hutch News

Hutch News

Stories tagged 'Marco Mielcarek'

Fred Hutch/SCCA transplant patient survival above the expected rate in U.S.

For 5th year in a row, bone marrow transplant program receives top recognition

Dec. 22, 2017 | By Molly McElroy

For the fifth year in a row, the Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance has been recognized by the Center for International Blood and Marrow Transplant Research as exceeding expectations for one-year survival rates. These survival rates specifically pertain to patients who have received transplants of blood-forming stem cells from healthy donors, a procedure pioneered at Fred Hutch.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Dec. 22, 2016

For fourth year in a row, Fred Hutch/SCCA transplant rates among best in the U.S.; immuntherapy symposium available on video for those who couldn't attend the event

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Feb. 4, 2016 | By Fred Hutch News Service staff

Drs. Marie Bleakley and Soheil Meshinchi receive $1M to design targeted immunotherapies for childhood leukemia; pancreatic cancer treatment advancing in clinical trials; novel mathematical model could transform dosage selection for clinical trials; new global initiative for breast cancer has roots in Seattle; Dr. Colin Correnti speaks at inaugural SHIFT 2016

View story >

Life with graft-vs.-host disease: When the transplant is just the beginning

How researchers are trying to combat this common, often debilitating side effect of treatment

April 21, 2015 | By Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant recipients, such as Greg Grappone, develop acute graft-vs.-host disease, which crops up within the first few months of treatment, and 40 percent get chronic GVHD, the form that appears more than 100 days post-transplant. As the name implies, the chronic condition can last for years — or a lifetime — and its symptoms range from mildly annoying to disabling to life-threatening.

View story >

Gentler treatment effective for many with graft-vs.-host disease

A new study finds halving standard steroid dose treats most acute GVHD just as well; could limit dangerous side effects

Feb. 19, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant patients develop acute graft-vs.-host disease. Standard treatment for GVHD, the steroid prednisone, carries its own host of side effects. Fred Hutch's Dr. Marco Mielcarek led a new study testing lower doses of prednisone in patients with acute GVHD -- with promising results.

View story >

Mielcarek lands $2.2 million GVHD grant

NHLBI grant will expand research into protective mechanisms of statins against severe acute graft-vs.-host disease in transplant patients

May 16, 2011 | By Dean Forbes

The Fred Hutchinson Cancer Research Center Clinical Research Division’s Dr. Marco Mielcarek has received $2.2 million from the National Institutes of Health’s National Heart, Lung and Blood Institute to continue research on whether statin treatment is effective at reducing the risk of graft-vs.-host disease in patients receiving an allogeneic stem cell transplant. While statins are a class of drugs for treating high cholesterol, they also have immune-modulating effects.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.